abstract: BACKGROUND: The combination of @entity900 and @entity1206 has been shown to be effective in @entity1 with advanced @entity1149 ( @entity1149 ). Based on these data, we planned to treat @entity1 with stage IIIB @entity1149 without @entity3483 and/or metastatic supraclavicular lymph nodes, in order to study the potential effectiveness of this association as neoadjuvant treatment. MATERIALS AND METHODS: Thirty @entity1 entered into the study and were treated preoperatively with @entity900 120 mg/m2 given on day 1 and @entity1206 30 mg/m2 given on days 1 and 8, recycled every 3 weeks for a maximum of 3 cycles. The main characteristics of @entity1 were: male/female 23/7, median age 61 years, performance status 0/1/2, 8/17/5. Only @entity1 who achieved an objective response underwent surgery. RESULTS: A total of 82 (91.1%) cycles were administered with moderate @entity137 : WHO grade (G) 2 and 3 @entity1398 occurred in 20 (66.6%) @entity1 , G 3 @entity417 occurred in 4 (13.3%), G 3 @entity390 / @entity391 in 20 (66.6%) and G 1-2 @entity8 in 2 (6.6%). Eighteen (60%; exact 95% confidence limits, 40.6% to 77.3%) @entity1 achieved a partial response and 14 (46.6%) underwent surgery. Complete resection (R0) was achieved in 11 (36.6% of all @entity1 ) and pathological complete resection in 5 (16.6%). No @entity260 were reported. The median survival for all @entity1 was 25.5 (exact 95% confidence limits, 13 to 39) months. The median progression-free survival in responsive @entity1 was 27 (exact 95% confidence limits, 13 to 33) months. CONCLUSION: The combination of @entity900 and @entity1206 is effective and safe as a neoadjuvant therapy in stage IIIB @entity1149 , showing a high response rate (60%) and amenability to surgery.

title: @entity900 plus XXXX as induction chemotherapy followed by surgery in the treatment of stage IIIB @entity1149 . Final results of a multicenter phase II study.

answer: @entity1206 :: (MESH:C030852,Chemical) :: ['vinorelbine']


abstract: @entity1129 carrying anhydrous @entity3265 ( @entity3655 ) fell off a freeway, releasing a dense cloud of @entity3655 gas, killing several @entity1 . The driver was dead upon impact. To our knowledge, pulmonary @entity3655 @entity137 in @entity1 has not been studied previously by electron microscopy (EM). Therefore, in two cases, the paraffin-embedded tissue blocks of lung were deparaffinized and reembedded in plastic for 1-mu sections and EM examination. The lung tissue of a third case, the truck driver, was similarly processed as a control. Light-microscopic pulmonary findings in the acute @entity3655 deaths included denudation of the tracheobronchial epithelium, @entity4 , and marked @entity4 , @entity384 , and @entity548 . In contrast, in the truck driver's lungs, the bronchial epithelium was intact, and there was no gross odor of @entity3655 . Massive @entity548 in his lungs were attributed to @entity130 rather than @entity3655 inhalation. EM examination of the lungs of the truck driver showed no discernible toxic alterations in either the capillary endothelial cells or the Type I or II alveolar epithelial cells, and alveolar and capillary basement membranes were intact. In contrast, EM study of the lungs from two individuals dying acutely of @entity3655 inhalation showed marked swelling and imbitional @entity4 of Type I alveolar epithelial cells; however, @entity133 membranes and capillary endothelial cells appeared as usual. These electron-microscopic findings demonstrate the Type I epithelial cell to be the target cell of acute alveolar wall injury in @entity3655 inhalation.

title: Ultrastructure of acute @entity3265 XXXX in the @entity1 lung.

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'people']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage', 'pulmonary hemorrhages']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['edema', 'alveolar edema', 'edema of the lamina propria']

entities_list: @entity384 :: ('MESH:D002311', 'Disease') :: ['congestion']

entities_list: @entity133 :: ('MESH:D002282', 'Disease') :: ['alveolar basement']

entities_list: @entity1129 :: ('MESH:D001260', 'Disease') :: ['A tanker truck']

answer: @entity137 :: (MESH:D064420,Disease) :: ['toxicity']


abstract: @entity1129 carrying anhydrous @entity3265 ( @entity3655 ) fell off a freeway, releasing a dense cloud of @entity3655 gas, killing several @entity1 . The driver was dead upon impact. To our knowledge, pulmonary @entity3655 @entity137 in @entity1 has not been studied previously by electron microscopy (EM). Therefore, in two cases, the paraffin-embedded tissue blocks of lung were deparaffinized and reembedded in plastic for 1-mu sections and EM examination. The lung tissue of a third case, the truck driver, was similarly processed as a control. Light-microscopic pulmonary findings in the acute @entity3655 deaths included denudation of the tracheobronchial epithelium, @entity4 , and marked @entity4 , @entity384 , and @entity548 . In contrast, in the truck driver's lungs, the bronchial epithelium was intact, and there was no gross odor of @entity3655 . Massive @entity548 in his lungs were attributed to @entity130 rather than @entity3655 inhalation. EM examination of the lungs of the truck driver showed no discernible toxic alterations in either the capillary endothelial cells or the Type I or II alveolar epithelial cells, and alveolar and capillary basement membranes were intact. In contrast, EM study of the lungs from two individuals dying acutely of @entity3655 inhalation showed marked swelling and imbitional @entity4 of Type I alveolar epithelial cells; however, @entity133 membranes and capillary endothelial cells appeared as usual. These electron-microscopic findings demonstrate the Type I epithelial cell to be the target cell of acute alveolar wall injury in @entity3655 inhalation.

title: Ultrastructure of acute XXXX @entity137 in the @entity1 lung.

answer: @entity3265 :: (MESH:D000641,Chemical) :: ['ammonia']


abstract: @entity1129 carrying anhydrous @entity3265 ( @entity3655 ) fell off a freeway, releasing a dense cloud of @entity3655 gas, killing several @entity1 . The driver was dead upon impact. To our knowledge, pulmonary @entity3655 @entity137 in @entity1 has not been studied previously by electron microscopy (EM). Therefore, in two cases, the paraffin-embedded tissue blocks of lung were deparaffinized and reembedded in plastic for 1-mu sections and EM examination. The lung tissue of a third case, the truck driver, was similarly processed as a control. Light-microscopic pulmonary findings in the acute @entity3655 deaths included denudation of the tracheobronchial epithelium, @entity4 , and marked @entity4 , @entity384 , and @entity548 . In contrast, in the truck driver's lungs, the bronchial epithelium was intact, and there was no gross odor of @entity3655 . Massive @entity548 in his lungs were attributed to @entity130 rather than @entity3655 inhalation. EM examination of the lungs of the truck driver showed no discernible toxic alterations in either the capillary endothelial cells or the Type I or II alveolar epithelial cells, and alveolar and capillary basement membranes were intact. In contrast, EM study of the lungs from two individuals dying acutely of @entity3655 inhalation showed marked swelling and imbitional @entity4 of Type I alveolar epithelial cells; however, @entity133 membranes and capillary endothelial cells appeared as usual. These electron-microscopic findings demonstrate the Type I epithelial cell to be the target cell of acute alveolar wall injury in @entity3655 inhalation.

title: Ultrastructure of acute @entity3265 @entity137 in the XXXX lung.

answer: @entity1 :: (9606,Species) :: ['human']


abstract: UNASSIGNED: @entity29030 ( @entity29030 ) is a @entity1800 with severe economic consequences for @entity12526 . Natural hosts for the @entity29030 virus (CSFV) are members of the family Suidae, i.e., Eurasian @entity1707 ( @entity1707 ) are also susceptible. @entity29030 in @entity1707 poses a serious threat to @entity12526 . CSFV is an enveloped RNA virus belonging to the pestivirus genus of the Flaviviridae family. Transmission of the @entity281 is usually by direct contact or by feeding of contaminated meat products. In recent decades @entity29030 has been successfully eradicated from Australia, North America, and the European Union. In areas with dense @entity1707 populations @entity29030 tends to become endemic whereas it is often self-limiting in small, less dense populations. In recent decades eradication strategies of @entity29030 in @entity1707 have been improved considerably. The reduction of the number of susceptible animals to a threshold level where the basic reproductive number is R 0 < 1 is the major goal of all control efforts. Depending on the epidemiological situation, hunting measures combined with strict hygiene may be effective in areas with a relatively low density of @entity1707 . Oral immunization was shown to be highly effective in endemic situations in areas with a high density of @entity1707 .

title: The control of classical swine fever in XXXX .

entities_list: @entity1707 :: ('9823', 'Species') :: ['wild boar', 'sus scrofa']

entities_list: @entity12526 :: ('9825', 'Species') :: ['domestic pigs']

entities_list: @entity29030 :: ('MESH:D006691', 'Disease') :: ['Classical swine fever', 'CSF']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity1800 :: ('MESH:D014777', 'Disease') :: ['viral disease']

answer: @entity1707 :: (9823,Species) :: ['wild boar']


abstract: We investigated the process of swallowing disturbance in the @entity1 with @entity746 ( @entity746 ). Swallowing function of 11 @entity1 with @entity746 (67.5 +/- 7.5 y.o.) was evaluated by videofluorography (VF) and swallowing part of @entity746 functional rating scale (FRSsw) more than 2 times during the course. Percent of forced vital capacity (%FVC) was also measured. VF measures were oral leakage, poor bolus formation, retention in oral cavity, abnormal transport to pharynx as oral stage and delayed swallowing reflex, laryngeal penetration, aspiration, nasal regurgitation, retention in valleculae and pyriform, and abnormal opening of pharyngo-esophageal segment as pharyngeal stage. FRSsw were defined as 4: normal eating habits, 3: early eating problems--occasional choking 2: dietary consistency changes, 1: needs supplemental tube feeding and 0:NPO (exclusively parental or enteral feeding). According to VF findings in the course of oral stage and pharyngeal stage, in some @entity1 , the disturbance of oral stage preceded that of pharyngeal stage, while in the other @entity1 , the disturbance of pharyngeal stage disturbance preceded that of oral stage, and in another @entity1 were mixed course. There was poor relationship between the FRSsw and VF measure. Even in the @entity1 of FRSsw 4 _ 3. penetration/aspiration were found. %FVC was 70.0 +/- 17.3% in @entity1 with FRSsw 4 _ 3, 43.1 +/- 17.6% in @entity1 with FRSsw 2 and 40.4 +/- 16.2% in @entity1 with FRS 1 _ 0. In the individual course, FRSsw decreased in parallel with %FVC. We conclude that there are various course of swallowing disturbance on VF findings, the oral stage disturbance proceed, the pharyngeal stage disturbance proceed or mixed. Swallowing function deteriorate in parallel with respiratory function in @entity746 @entity1 . We have to take measures against the @entity1282 even in early stage.

title: [Process of swallowing disturbance in XXXX --evaluation of videofluorography and respiratory function].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1282 :: ('MESH:D003680', 'Disease') :: ['dysphagia']

entities_list: @entity746 :: ('MESH:D000690', 'Disease') :: ['amyotrophic lateral sclerosis', 'ALS']

answer: @entity746 :: (MESH:D000690,Disease) :: ['amyotrophic lateral sclerosis']


abstract: The effects of fetal pancreatectomy on the uptake of @entity26 , @entity413 and @entity880 by the fetus, uterus and uteroplacental tissues were investigated in chronically catheterized @entity742 during the last third of gestation. Pancreatectomy reduced the uptake of @entity413 by the fetus but had little apparent effect on @entity413 uptake by the uterus or uteroplacental tissues. The mean umbilical uptake of @entity413 by the pancreatectomized fetuses was 10.4 +/- 1.1 mumol/kg . min (n = 4) which was significantly less than the value observed in the intact fetuses (24.5 +/- 2.7 mumol/kg . min, n = 4, P less than 0.01). When all the data from the pancreatectomized and intact fetuses were combined, there was a significant positive correlation between the plasma @entity26434 concentration in utero and the umbilical uptake of @entity413 (r = 0.95, n = 14, P less than 0.01). The @entity413 / @entity26 quotient in the pancreatectomized fetuses (0.32 +/- 0.02, n = 9) was significantly less than the value observed in the intact fetuses (0.59 +/- 0.04, n = 6, P less than 0.01). There was also a significant positive correlation between the @entity413 / @entity26 quotient and the plasma concentration of @entity26434 in the fetus (r = 0.73, n = 59, P less than 0.01). Pancreatectomy had no significant effect on the fetal @entity880 / @entity26 quotient or on the uptake of @entity26 or @entity880 by any of the tissues. These observations demonstrate that the endogenous concentration of @entity26434 is a physiological regulator of @entity413 uptake by the fetal tissues.

title: The effect of pancreatectomy on the uptake of metabolites by the XXXX fetus.

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity742 :: (9940,Species) :: ['sheep']


abstract: UNASSIGNED: Cryotherapy (or cold treatment) has been a popular treatment to relieve @entity158 caused by injuries to tissues such as tendons. However, the exact mechanisms behind the beneficial effects of cryotherapy in tendons remain largely unclear. As @entity1421 ( @entity1421 ) is known to be a major mediator of acute @entity32 in tissues, which is related to tissue @entity158 , we hypothesized that the beneficial effects of cryotherapy in tendons are mediated by downregulation of @entity1421 levels. To test this hypothesis, we applied cold treatment to @entity19 @entity924 using two animal models: exhaustive @entity19 treadmill running and acute @entity19 @entity1796 by needle penetration. We then measured the levels of @entity1421 and protein expression levels of @entity10178 , an enzyme responsible for @entity1421 production in tissues, under both experimental conditions. We found that treadmill running increased @entity1421 levels in both @entity924 compared to control @entity19 without running. Cold treatment for 30 min after treadmill running was sufficient to reduce @entity1421 levels to near baseline control levels in both tendons. An extension of cold treatment to 60 min resulted only in a marginal @entity924 , but a marked @entity924 . Moreover, @entity10178 protein levels in both tendons were also lowered by cold treatment, suggesting that the reduction of @entity1421 levels in tendons by cold treatment is at least in part due to the decreased @entity10178 expression. Similarly, in the acutely injured tendons, 30 min of cold treatment after needle penetration reduced @entity1421 levels when compared to the controls at room temperature (22  C). This decrease was sustained up to at least 3 h after the administration of cryotherapy. Given that @entity1421 is a known @entity158 sensitiser, the results of this study suggest that the ability of cold treatment to reduce @entity158 may be attributable to its ability to decrease @entity1421 production in tendons.

title: Cryotherapy suppresses XXXX in an animal model.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity1421 :: ('MESH:D015232', 'Chemical') :: ['PGE2', 'prostaglandin E2']

entities_list: @entity924 :: ('MESH:D052256', 'Disease') :: ['patellar and Achilles tendons', 'decrease in patellar tendons', 'decrease in Achilles tendons']

entities_list: @entity1796 :: ('MESH:D013708', 'Disease') :: ['tendon injury']

answer: @entity32 :: (MESH:D007249,Disease) :: ['tendon inflammation']


abstract: @entity1 with @entity30 (n = 22), @entity31 (n = 5), inactive @entity1595 (n = 1), @entity1744 (n = 2), @entity625 (n = 1) and @entity2550 (n = 2) were examined with 111In- @entity4344 labelled "mixed" leukocyte preparations (n = 12) or with @entity4769 labelled "pure" granulocyte preparations (n = 21). Compared with barium enemas of the gut and colonoscopy, performed within of one week in 31 @entity1 there was a correct location of infiltrated bowel segments in 24 @entity1 (78%). The scan diagnosed more infiltrated segments in 4 @entity1 (13%). In 3 @entity1 it failed to diagnose one inflamed segment. In 24 @entity1 the faecal 111In-excretion was expressed as percentage of the reinjected 111In-activity. All @entity1 with non @entity29 and @entity1 with inactive @entity29 excreted less than 2% of the reinjected 111In-activity. All but one female @entity1 with active @entity29 excreted more than 2%. In 24 @entity1 the correlation of ESR, CDAI and A.I. was available. There was a good correlation between ESR (r = 0.77, P less than 0.001), A.I. (r = 0.61, p less than 0.001) and the %-faecal @entity644 . The 111In-labelling of white blood cells, especially of granulocytes, seems to be a reliable alternative method to localize infiltrated bowel segments and to assess disease activity in @entity1 with @entity29 , compared to usually performed radiological, endoscopical and clinical methods.

title: [ XXXX marked leukocytes: a method for diagnosing the location and evaluating the activity of @entity30 and @entity31 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['faecal excretion']

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis']

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's disease"]

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['bowel disease', 'inflammatory bowel diseases']

entities_list: @entity1595 :: ('MESH:D008061', 'Disease') :: ["Whipple's disease"]

entities_list: @entity2550 :: ('MESH:D015009', 'Disease') :: ['Yersinia infections']

entities_list: @entity1744 :: ('MESH:D043183', 'Disease') :: ['irritable bowel syndrome']

answer: @entity4769 :: (MESH:C032950,Chemical) :: ['111In-oxine']


abstract: @entity1 with @entity30 (n = 22), @entity31 (n = 5), inactive @entity1595 (n = 1), @entity1744 (n = 2), @entity625 (n = 1) and @entity2550 (n = 2) were examined with 111In- @entity4344 labelled "mixed" leukocyte preparations (n = 12) or with @entity4769 labelled "pure" granulocyte preparations (n = 21). Compared with barium enemas of the gut and colonoscopy, performed within of one week in 31 @entity1 there was a correct location of infiltrated bowel segments in 24 @entity1 (78%). The scan diagnosed more infiltrated segments in 4 @entity1 (13%). In 3 @entity1 it failed to diagnose one inflamed segment. In 24 @entity1 the faecal 111In-excretion was expressed as percentage of the reinjected 111In-activity. All @entity1 with non @entity29 and @entity1 with inactive @entity29 excreted less than 2% of the reinjected 111In-activity. All but one female @entity1 with active @entity29 excreted more than 2%. In 24 @entity1 the correlation of ESR, CDAI and A.I. was available. There was a good correlation between ESR (r = 0.77, P less than 0.001), A.I. (r = 0.61, p less than 0.001) and the %-faecal @entity644 . The 111In-labelling of white blood cells, especially of granulocytes, seems to be a reliable alternative method to localize infiltrated bowel segments and to assess disease activity in @entity1 with @entity29 , compared to usually performed radiological, endoscopical and clinical methods.

title: [ @entity4769 marked leukocytes: a method for diagnosing the location and evaluating the activity of XXXX and @entity31 ].

answer: @entity30 :: (MESH:D003424,Disease) :: ['Crohn disease']


abstract: @entity1 with @entity30 (n = 22), @entity31 (n = 5), inactive @entity1595 (n = 1), @entity1744 (n = 2), @entity625 (n = 1) and @entity2550 (n = 2) were examined with 111In- @entity4344 labelled "mixed" leukocyte preparations (n = 12) or with @entity4769 labelled "pure" granulocyte preparations (n = 21). Compared with barium enemas of the gut and colonoscopy, performed within of one week in 31 @entity1 there was a correct location of infiltrated bowel segments in 24 @entity1 (78%). The scan diagnosed more infiltrated segments in 4 @entity1 (13%). In 3 @entity1 it failed to diagnose one inflamed segment. In 24 @entity1 the faecal 111In-excretion was expressed as percentage of the reinjected 111In-activity. All @entity1 with non @entity29 and @entity1 with inactive @entity29 excreted less than 2% of the reinjected 111In-activity. All but one female @entity1 with active @entity29 excreted more than 2%. In 24 @entity1 the correlation of ESR, CDAI and A.I. was available. There was a good correlation between ESR (r = 0.77, P less than 0.001), A.I. (r = 0.61, p less than 0.001) and the %-faecal @entity644 . The 111In-labelling of white blood cells, especially of granulocytes, seems to be a reliable alternative method to localize infiltrated bowel segments and to assess disease activity in @entity1 with @entity29 , compared to usually performed radiological, endoscopical and clinical methods.

title: [ @entity4769 marked leukocytes: a method for diagnosing the location and evaluating the activity of @entity30 and XXXX ].

answer: @entity31 :: (MESH:D003093,Disease) :: ['ulcerative colitis']


abstract: @entity4479 @entity95 were immunized with @entity291 retina and complete Freund's adjuvant by the intradermal route. Blood was obtained by complete bleeding of the @entity95 and stored at -20 degrees C. Their eyes were enucleated and submitted to histopathological techniques. Humoral antiretinal antibodies were detected by Ouchterlony, immunoelectrophoresis and crossed-immunoelectrophoresis, yielding precipitins presumably of the IgG type. Sensitized lymphocytes were also detected by their incubation with the retinal extract and the soluble fractions belonging to the peaks no 1 and no 2 ("S antigen") in the @entity72305 and TTL techniques. The whole extract was passed through a Sephadex G 100 and DEAE cellulose columns and several soluble fractions were obtained. Two major protein peaks were detected (no 1 and no 2) that were subdivided into five other protein peaks (1A, 1B, 2A, 2B and 2C). Sugars were not present and molecular weights were 50,000 daltons for peak no 2 and higher than 66.000 for peak no 1. The whole protein content of the extract and of the different soluble fractions were established by the Lowry method. Histopathological studies revealed extensive lesions of the uveal tract consisting of a cellular infiltrate rich in lymphocytes and monocytes. Increased vascularization of retina was also appreciated. This experimental model represents a guide in the approach to the @entity1 @entity1596 of unknown origin whose immunological findings will be presented in a forthcoming issue.

title: [Autoimmune uveitis. I. Immunochemical properties of the soluble fractions of XXXX retina].

entities_list: @entity4479 :: ('MESH:C538052', 'Disease') :: ['Adult albino']

answer: @entity291 :: (9913,Species) :: ['bovine']


abstract: Twenty-two @entity1 underwent aortic valve replacement for @entity472 with a preoperative ejection fraction less than 45%. Three @entity1 died peroperatively and a fourth @entity1 died 18 months later before the haemodynamic control. The other 18 @entity1 were systematically reinvestigated, on average 16 months after surgery. Sixteen had a remarkable functional improvement and a significant increase in ejection fraction at haemodynamic control: 32 +/- 6% to 61 +/- 8%, p less than 0.001. They were surgical successes (Group I). In this group, the 7 @entity1 with the most severe alteration of ventricular function and an average ejection fraction of: 26 +/- 3%, also improved to near normal function with a postoperative fraction of 62 +/- 11%. There was no significant improvement of the ejection fraction in 2 @entity1 , and they were classified with the fatalities as @entity177 (Group II). The clinical, electrocardiographic, radiological, haemodynamic and angiographic data of these two populations were compared to try and identify preoperative indices of prognostic value. Only the angiographic left ventricular myocardial mass index (LVMI) was significantly higher in Group II (253 +/- 98 g/m2) than in Group I (156 +/- 56 g/m2, p less than 0.05). A discriminating analysis showed that the most important parameters to separate the 2 groups of @entity1 were the LVMI and the thickness of the left ventricular wall. The marked increase of the postoperative ejection fraction in 3/4 of our @entity1 confirmed the clinical value of valvular replacement justifying the indication for surgery in @entity1 with severe @entity472 in spite of a severe alteration of left ventricular function.

title: [ XXXX with low preoperative ejection fraction. Long-term postoperative hemodynamic and angiographic studies].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity472 :: ('MESH:D001024', 'Disease') :: ['aortic stenosis']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['surgical failures']

answer: @entity472 :: (MESH:D001024,Disease) :: ['Aortic stenosis']


abstract: Twenty-five @entity1 with @entity1121 confirmed by clinical, echocardiographic and haemodynamic investigations were treated with high dose @entity1169 (320 to 800 mg/day, average 420 mg/day) and assessed after an average follow-up period of 25 months. The effects of treatment were assessed by interrogation in all @entity1 and by exercise testing before and after @entity1169 in 19 cases. Comparative echocardiographic (21 @entity1 ) Holter (20 @entity1 ) and catheter studies (14 @entity1 ) were also performed. The cardiovascular mortality rate during the study period was nil. All @entity1 were symptomatic before treatment; 9 became asymptomatic and 13 @entity1 were improved, the average functional score decreasing from 5.16 +/- 2.15 to 2.28 +/- 1.49 (p less than 0.001). The persistence of severe symptoms led to withdrawal of the beta-blocker in 2 cases. There was a parallel improvement in maximal work capacity during exercise stress testing (96 +/- 27 watts vs 117 +/- 30 watts, p less than 0.01). A resting intraventricular pressure gradient was recorded in 12 of the 14 @entity1 undergoing repeat catheter study which decreased after @entity1169 from an average of 66.75 +/- 32.72 mmHg to 42.75 +/- 37.6 mmHg (p less than 0.05). Left ventricular end diastolic pressures remained unchanged. The change in pressure gradient did not correlate with the symptomatology and there were no associated echocardiographic changes. The Holter monitoring did not show any improvement of ventricular hyperexcitability under @entity1169 : the number of @entity1 with complex @entity943 remained unchanged (7 @entity1 ).(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Outcome of XXXX treated with high doses of @entity1169 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1121 :: ('MESH:D002312', 'Disease') :: ['hypertrophic obstructive cardiomyopathy']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['ventricular arrhythmias']

entities_list: @entity1169 :: ('MESH:D011433', 'Chemical') :: ['propranolol']

answer: @entity1121 :: (MESH:D002312,Disease) :: ['hypertrophic and obstructive myocardiopathies']


abstract: Twenty-five @entity1 with @entity1121 confirmed by clinical, echocardiographic and haemodynamic investigations were treated with high dose @entity1169 (320 to 800 mg/day, average 420 mg/day) and assessed after an average follow-up period of 25 months. The effects of treatment were assessed by interrogation in all @entity1 and by exercise testing before and after @entity1169 in 19 cases. Comparative echocardiographic (21 @entity1 ) Holter (20 @entity1 ) and catheter studies (14 @entity1 ) were also performed. The cardiovascular mortality rate during the study period was nil. All @entity1 were symptomatic before treatment; 9 became asymptomatic and 13 @entity1 were improved, the average functional score decreasing from 5.16 +/- 2.15 to 2.28 +/- 1.49 (p less than 0.001). The persistence of severe symptoms led to withdrawal of the beta-blocker in 2 cases. There was a parallel improvement in maximal work capacity during exercise stress testing (96 +/- 27 watts vs 117 +/- 30 watts, p less than 0.01). A resting intraventricular pressure gradient was recorded in 12 of the 14 @entity1 undergoing repeat catheter study which decreased after @entity1169 from an average of 66.75 +/- 32.72 mmHg to 42.75 +/- 37.6 mmHg (p less than 0.05). Left ventricular end diastolic pressures remained unchanged. The change in pressure gradient did not correlate with the symptomatology and there were no associated echocardiographic changes. The Holter monitoring did not show any improvement of ventricular hyperexcitability under @entity1169 : the number of @entity1 with complex @entity943 remained unchanged (7 @entity1 ).(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Outcome of @entity1121 treated with high doses of XXXX ].

answer: @entity1169 :: (MESH:D011433,Chemical) :: ['propranolol']


abstract: BACKGROUND: This study was conducted to establish the minimal detectable change (MDC) and @entity922 ( @entity922 ) of the physical category of the @entity64 -Specific Quality of Life Scale in @entity1 with @entity64 . METHODS: MDC and @entity922 scores were calculated from the data of 74 @entity1 enrolled in randomized controlled trials investigating the effects of two rehabilitation programs in @entity1 with @entity64 . These @entity1 received treatments for 3 weeks and underwent clinical assessment before and after treatment. To obtain test-retest reliability for calculating MDC, another 25 @entity1 with @entity64 were recruited. The MDC was calculated from the standard error of measurement (SEM) to indicate a real change with 95% confidence for individual @entity1 (MDC95). Distribution-based and anchor-based methods were adopted to triangulate the ranges of minimal @entity922 . The percentage of scale width was calculated by dividing the MDC and @entity922 by the total score range of each physical category. The percentage of @entity1 exceeding MDC95 and minimal @entity922 was also reported. RESULTS: The MDC95 of the mobility, self-care, and @entity2045 ( @entity2045 ) function subscales were 5.9, 4.0, and 5.3 respectively. The minimal CID ranges for these 3 subscales were 1.5 to 2.4, 1.2 to 1.9, and 1.2 to 1.8. The percentage of @entity1 exceeding MDC95 and minimal @entity922 of the mobility, self-care, and @entity2045 function subscales were 9.5% to 28.4%, 6.8% to 28.4%, and 12.2% to 33.8%, respectively. CONCLUSIONS: The change score of an individual @entity1 has to reach 5.9, 4.0, and 5.3 on the 3 subscales to indicate a true change. The mean change scores of a group of @entity1 with @entity64 on these subscales should reach the lower bound of CID ranges of 1.5 (6.3% scale width), 1.2 (6.0% scale width), and 1.2 (6.0% scale width) to be regarded as clinically important change. This information may facilitate interpretations of @entity1 -reported outcomes after @entity64 rehabilitation. Future research is warranted to validate these findings.

title: Assessing the @entity64 -specific quality of life for outcome measurement in XXXX rehabilitation: minimal detectable change and clinically important difference.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'patient']

entities_list: @entity2045 :: ('MESH:D009207', 'Disease') :: ['UE', 'upper extremity']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke', 'chronic stroke', 'Stroke']

entities_list: @entity922 :: ('MESH:D013568', 'Disease') :: ['clinically important differences', 'CIDs']

answer: @entity64 :: (MESH:D020521,Disease) :: ['stroke']


abstract: BACKGROUND: This study was conducted to establish the minimal detectable change (MDC) and @entity922 ( @entity922 ) of the physical category of the @entity64 -Specific Quality of Life Scale in @entity1 with @entity64 . METHODS: MDC and @entity922 scores were calculated from the data of 74 @entity1 enrolled in randomized controlled trials investigating the effects of two rehabilitation programs in @entity1 with @entity64 . These @entity1 received treatments for 3 weeks and underwent clinical assessment before and after treatment. To obtain test-retest reliability for calculating MDC, another 25 @entity1 with @entity64 were recruited. The MDC was calculated from the standard error of measurement (SEM) to indicate a real change with 95% confidence for individual @entity1 (MDC95). Distribution-based and anchor-based methods were adopted to triangulate the ranges of minimal @entity922 . The percentage of scale width was calculated by dividing the MDC and @entity922 by the total score range of each physical category. The percentage of @entity1 exceeding MDC95 and minimal @entity922 was also reported. RESULTS: The MDC95 of the mobility, self-care, and @entity2045 ( @entity2045 ) function subscales were 5.9, 4.0, and 5.3 respectively. The minimal CID ranges for these 3 subscales were 1.5 to 2.4, 1.2 to 1.9, and 1.2 to 1.8. The percentage of @entity1 exceeding MDC95 and minimal @entity922 of the mobility, self-care, and @entity2045 function subscales were 9.5% to 28.4%, 6.8% to 28.4%, and 12.2% to 33.8%, respectively. CONCLUSIONS: The change score of an individual @entity1 has to reach 5.9, 4.0, and 5.3 on the 3 subscales to indicate a true change. The mean change scores of a group of @entity1 with @entity64 on these subscales should reach the lower bound of CID ranges of 1.5 (6.3% scale width), 1.2 (6.0% scale width), and 1.2 (6.0% scale width) to be regarded as clinically important change. This information may facilitate interpretations of @entity1 -reported outcomes after @entity64 rehabilitation. Future research is warranted to validate these findings.

title: Assessing the XXXX -specific quality of life for outcome measurement in @entity64 rehabilitation: minimal detectable change and clinically important difference.

answer: @entity64 :: (MESH:D020521,Disease) :: ['stroke']


abstract: BACKGROUND: Lipoprotein-associated phospholipase A    (Lp- @entity1989   ) is a recently identified and potentially useful plasma biomarker for cardiovascular and @entity731 . However, the correlation between the Lp- @entity1989    activity and @entity2998 remains poorly investigated in @entity1 with @entity209 ( @entity209 ). The present study aimed to evaluate the potential role of Lp- @entity1989    as a comprehensive marker of @entity209 in individuals with and without @entity2998 . METHODS: We documented 118 consecutive @entity1 with @entity209 and 70 age- and sex-matched healthy subjects served as controls. The @entity1 were further divided into two groups: 39 with carotid plaques and 79 without carotid plaques to elucidate the influence of Lp- @entity1989    on @entity2998 . The plasma Lp- @entity1989    activity was measured by using ELISA method and carotid @entity1004 ( @entity1004 ) was performed by ultrasound in all @entity1 . RESULTS: Lp- @entity1989    activity was significantly increased in @entity209 subgroups when compared with controls, and was higher in @entity1 with carotid plaques than those without plaques (P < 0.05). Furthermore, we found that significant difference in Lp- @entity1989    was obtained between @entity1 with three and four disorders of @entity209 (P < 0.01). Age (b = 0.183, P = 0.029), LDL- @entity165 (b = 0.401, P = 0.000) and waist-hip ratio (b = 0.410, P = 0.000) emerged as significant and independent determinants of Lp- @entity1989    activity. Multiple stepwise regression analysis revealed that LDL- @entity165 (b = 0.309, P = 0.000), systolic blood pressure (b = 0.322, P = 0.002) and age (b = 0.235, P = 0.007) significantly correlated with max @entity1004 , and @entity6511 was not an independent predictor for @entity1004 . CONCLUSIONS: Lp- @entity1989    may be a modulating factor for @entity1004 via age and LDL- @entity165 , not independent predictor in the pathophysiological process of @entity2998 in @entity1 with @entity209 .

title: Plasma lipoprotein-associated phospholipase A2 in @entity1 with @entity209 and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients']

entities_list: @entity1004 :: ('MESH:C563733', 'Disease') :: ['intimal-media thickness', 'carotid IMT', 'IMT']

entities_list: @entity2998 :: ('MESH:D002340', 'Disease') :: ['carotid atherosclerosis']

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome', 'MetS']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic diseases']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity2998 :: (MESH:D002340,Disease) :: ['carotid atherosclerosis']


abstract: BACKGROUND: Lipoprotein-associated phospholipase A    (Lp- @entity1989   ) is a recently identified and potentially useful plasma biomarker for cardiovascular and @entity731 . However, the correlation between the Lp- @entity1989    activity and @entity2998 remains poorly investigated in @entity1 with @entity209 ( @entity209 ). The present study aimed to evaluate the potential role of Lp- @entity1989    as a comprehensive marker of @entity209 in individuals with and without @entity2998 . METHODS: We documented 118 consecutive @entity1 with @entity209 and 70 age- and sex-matched healthy subjects served as controls. The @entity1 were further divided into two groups: 39 with carotid plaques and 79 without carotid plaques to elucidate the influence of Lp- @entity1989    on @entity2998 . The plasma Lp- @entity1989    activity was measured by using ELISA method and carotid @entity1004 ( @entity1004 ) was performed by ultrasound in all @entity1 . RESULTS: Lp- @entity1989    activity was significantly increased in @entity209 subgroups when compared with controls, and was higher in @entity1 with carotid plaques than those without plaques (P < 0.05). Furthermore, we found that significant difference in Lp- @entity1989    was obtained between @entity1 with three and four disorders of @entity209 (P < 0.01). Age (b = 0.183, P = 0.029), LDL- @entity165 (b = 0.401, P = 0.000) and waist-hip ratio (b = 0.410, P = 0.000) emerged as significant and independent determinants of Lp- @entity1989    activity. Multiple stepwise regression analysis revealed that LDL- @entity165 (b = 0.309, P = 0.000), systolic blood pressure (b = 0.322, P = 0.002) and age (b = 0.235, P = 0.007) significantly correlated with max @entity1004 , and @entity6511 was not an independent predictor for @entity1004 . CONCLUSIONS: Lp- @entity1989    may be a modulating factor for @entity1004 via age and LDL- @entity165 , not independent predictor in the pathophysiological process of @entity2998 in @entity1 with @entity209 .

title: Plasma lipoprotein-associated phospholipase A2 in @entity1 with XXXX and @entity2998 .

answer: @entity209 :: (MESH:D008659,Disease) :: ['metabolic syndrome']


abstract: BACKGROUND: Lipoprotein-associated phospholipase A    (Lp- @entity1989   ) is a recently identified and potentially useful plasma biomarker for cardiovascular and @entity731 . However, the correlation between the Lp- @entity1989    activity and @entity2998 remains poorly investigated in @entity1 with @entity209 ( @entity209 ). The present study aimed to evaluate the potential role of Lp- @entity1989    as a comprehensive marker of @entity209 in individuals with and without @entity2998 . METHODS: We documented 118 consecutive @entity1 with @entity209 and 70 age- and sex-matched healthy subjects served as controls. The @entity1 were further divided into two groups: 39 with carotid plaques and 79 without carotid plaques to elucidate the influence of Lp- @entity1989    on @entity2998 . The plasma Lp- @entity1989    activity was measured by using ELISA method and carotid @entity1004 ( @entity1004 ) was performed by ultrasound in all @entity1 . RESULTS: Lp- @entity1989    activity was significantly increased in @entity209 subgroups when compared with controls, and was higher in @entity1 with carotid plaques than those without plaques (P < 0.05). Furthermore, we found that significant difference in Lp- @entity1989    was obtained between @entity1 with three and four disorders of @entity209 (P < 0.01). Age (b = 0.183, P = 0.029), LDL- @entity165 (b = 0.401, P = 0.000) and waist-hip ratio (b = 0.410, P = 0.000) emerged as significant and independent determinants of Lp- @entity1989    activity. Multiple stepwise regression analysis revealed that LDL- @entity165 (b = 0.309, P = 0.000), systolic blood pressure (b = 0.322, P = 0.002) and age (b = 0.235, P = 0.007) significantly correlated with max @entity1004 , and @entity6511 was not an independent predictor for @entity1004 . CONCLUSIONS: Lp- @entity1989    may be a modulating factor for @entity1004 via age and LDL- @entity165 , not independent predictor in the pathophysiological process of @entity2998 in @entity1 with @entity209 .

title: Plasma lipoprotein-associated phospholipase A2 in XXXX with @entity209 and @entity2998 .

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: Abnormal Wnt signaling and impaired cell-cell adhesion due to abnormal @entity5962 and @entity3546 function have been implicated in many @entity5 , but have not been fully explored in @entity189 . The aim of this study was to analyze @entity3546 cellular location and @entity5962 expression levels in @entity189 . @entity5962 expression levels were also correlated with clinical data and underlying pathology. @entity3546 and @entity5962 expression were examined in 18 @entity189 and 7 non-tumoral inflammatory pharynx tissues using immunohistochemical methods. @entity1 clinical data were collected, and histological evaluation was performed by @entity1710 / @entity1711 staining. @entity3546 was detected in membrane and cytoplasm in all cases of @entity189 , regardless of histological type; in non-tumoral tissues, however, @entity3546 was observed only in the membrane. As for @entity5962 expression levels, strong staining was observed in most non-tumoral tissues, but staining was only moderate in @entity189 tissues. @entity5962 expression was associated with @entity3546 localization, study group, @entity3 , and @entity1 outcomes. Reduced levels of @entity5962 protein observed in nasopharyngeal carinoma may play an important role in invasion and @entity3 . Cytoplasmic @entity3546 in @entity189 may impair cell-cell adhesion, promoting invasive behavior and a @entity3 phenotype.

title: The cadherin-catenin complex in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'Patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['nasopharyngeal carcinoma']

entities_list: @entity1710 :: ('MESH:D006416', 'Chemical') :: ['hematoxylin']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease', 'metastasis', 'metastatic tumor']

answer: @entity189 :: (MESH:D002277,Disease) :: ['nasopharyngeal carcinoma']


abstract: Eighteen @entity1 with sustained @entity1165 underwent serial electrophysiological studies to establish the therapeutic efficacy of @entity2778 as compared to other available anti-arrhythmic agents. One or more acutely effective drug was found in 14 of the 18 @entity1 (78%). @entity2778 was tested in all 18 @entity1 and was effective in 12 of them (67%). For assessment of the prophylactic efficacy of other anti-arrhythmic agents, an average of 3.5 additional studies per @entity1 were performed resulting in successful prevention of @entity1165 in a total of 10 of 63 (16%) additional trials. Nine @entity1 were placed on chronic oral therapy with @entity2778 . In these nine @entity1 long-term prophylaxis against @entity1165 was documented over a mean follow-up period of 9.6 months (range 2-18 months). The study suggests that @entity2778 can provide effective prophylaxis against @entity1165 in a significant proportion of @entity1 refractory to other available drugs and that this prophylactic efficacy is predominantly due to its Class III anti-arrhythmic properties. Experimental studies were performed in eight conscious @entity235 3-7 days following proximal LAD ligation. Epicardial recordings were obtained using implanted composite electrodes. @entity2778 prevented sustained VT by a predominant increase in refractoriness of the infarcted zone. In vitro, @entity2778 caused a significant prolongation of the action potential of @entity1188 . Refractoriness of epicardial ventricular fibres was significantly more prolonged in ischemically damaged cells as compared to normal fibres.

title: Contribution of delayed ventricular repolarization to the anti-arrhythmic efficacy of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1165 :: ('MESH:D017180', 'Disease') :: ['ventricular tachycardia']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['epicardial and endocardial fibres within both the infarcted and noninfarcted myocardium']

entities_list: @entity2778 :: ('MESH:D013015', 'Chemical') :: ['Sotalol', 'sotalol']

answer: @entity2778 :: (MESH:D013015,Chemical) :: ['sotalol']


abstract: This report concerns 30 @entity1 with the acute form of " @entity439 " of the aorta treated during a 27-year period between April 1957 and March 1984. There were 28 @entity1 and two @entity1 whose ages ranged from 46 to 78 years (most over 60 years). All were heavy smokers. The @entity439 was located below the renal arteries and the inflammatory changes were limited to the abdomen in 24 @entity1 ; one @entity1 had a @entity1756 . The @entity439 involved the entire abdominal aorta in one, the descending thoracic and infrarenal abdominal aorta in two, and the descending thoracic and abdominal aorta in continuity in three @entity1 . The inflammatory changes occurred grossly and microscopically in both abdominal and thoracic aortic segments in five of the latter six @entity1 . The changes were manifested by anterior and lateral mural inflammatory thickening contiguous with similar changes of the retroperitoneum and mediastinum that produced varying degrees of @entity1695 in seven @entity1 . Most had @entity615 and abdominal tenderness, suggesting @entity397 . Emergency exploratory operation had been performed elsewhere in 10 @entity1 . Operation was abandoned because of exposure difficulties, bowel perforation, or visceral arterial involvement. Diagnosis was suggested by CT scan in 10, ultrasonography in one, and excretory urograms in seven @entity1 . Treatment consisted of thoracoabdominal aortic replacement in six and infrarenal aortic replacement in 24. The aorta was clamped at the diaphragm in most of the latter cases to avoid injury to adjacent structures. Nephrectomy or ureterolysis was rarely necessary. Of these 30 @entity1 , 29 were early (30 day) survivors and @entity1695 spontaneously subsided in most cases without special treatment. There was one late death at 2 months and eight deaths from 3 to 13 years; 20 (67%) @entity1 are still alive.

title: Inflammatory XXXX of the aorta.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'men']

entities_list: @entity1695 :: ('MESH:D014517', 'Disease') :: ['ureteral obstruction']

entities_list: @entity615 :: ('MESH:D001416', 'Disease') :: ['abdominal, back, or flank pain']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysmal disease', 'aneurysm', 'inflammatory aneurysm']

entities_list: @entity397 :: ('MESH:D012421', 'Disease') :: ['rupture or leakage']

entities_list: @entity1756 :: ('MESH:D017542', 'Disease') :: ['ruptured aneurysm']

answer: @entity439 :: (MESH:D000783,Disease) :: ['aneurysms']


abstract: Effects of prolonged administration of compound 48/80 (48/80) on the gastric mucosa, @entity750 and @entity112 levels in serum, and mast cells of @entity35 were studied. Daily administration of 48/80 (0.75 mg/kg, i.p.) for 2 or 4 days produced widespread @entity1819 . Further administration of the agent for up to 12 days did not aggravate the lesions which had developed in the early period of administration of the drug. There were only a few visible lesions and numerous healed ones. Almost the same phenomenon was observed with the daily administration of @entity750 plus @entity112 (10 mg/kg each, i.p.) for 2 to 12 days. While 48/80 given for 2 or 4 days increased @entity750 and @entity112 levels in serum, it induced no appreciable increase of these @entity4478 after 8 or 12 days of treatment. @entity750 and @entity112 levels in peritoneal mast cells significantly decreased after the treatment with 48/80 over a 4 day period. The decrease in @entity1819 after prolonged treatment with 48/80 is due to both the depletion of @entity750 and @entity112 from mast cells and an increased resistance of the gastric mucosa with healed lesions.

title: Effects of prolonged treatment with compound 48/80 on the gastric mucosa and mast cells in the XXXX .

entities_list: @entity1819 :: ('MESH:D013272', 'Disease') :: ['gastric lesions']

entities_list: @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin', 'Serotonin']

entities_list: @entity112 :: ('MESH:D006632', 'Chemical') :: ['histamine']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: A strain of @entity8171 isolated from the feces of a @entity1 with @entity294 was examined for growth kinetics and toxic exoproduct formation using the complete (BHI) and synthetic culture media. It was found that the test organism in synthetic medium grew distinctly slower than in BHI. Fractionations on Sephadex G-100 column yielded 3 fractions from the complete medium culture filtrate and 2 fractions from the culture filtrate obtained from synthetic medium. The first culture filtrate fractions (F1) were represented by components of the molecular weight over 100,000, the respective second fractions (F2) from complete and synthetic medium were of the molecular weights of about 40,000 and 10,000. In the early skin test on @entity95 the @entity137 of culture filtrates and their fractions manifested itself by an increased permeability of blood vessels, in the late skin test by a hemorrhagic reaction associated with dilatation of blood vessels and induration of the skin tissue. In a test on @entity19 foot pad all separated filtrate fractions gave a positive @entity4 reaction. In cultured Vero cells samples of synthetic medium fractions gave a distinct cytotoxic reaction. Immunochemically, the presence of @entity558 in culture filtrates as well as some variations in the antigenicity of components from the complete and synthetic medium fractions were found. Apart from @entity558 some additional high-molecular-weight components were also present in the toxic complex of both first filtrate fractions (F1). Much more attention should be given to analysis of these first fraction complexes as well as to toxinogenicity of second fractions (F2) using some additional tests.

title: Toxic exoproducts of XXXX .

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['edematous']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhoea']

entities_list: @entity8171 :: ('546', 'Species') :: ['Citrobacter freundii']

answer: @entity8171 :: (546,Species) :: ['citrobacter freundii']


abstract: We report eyelid margin changes in 3 @entity1 after @entity1205 treatment for @entity0 . These @entity1 were referred to Cincinnati Eye Institute for eyelash @entity9467 and all had been treated with @entity1205 in the near past. The @entity32269 started soon after chemotherapy. All 3 cases showed varying degrees of @entity32 and cicatricial changes leading to marginal entropion. The first @entity1 exhibited very prominent eyelid margin @entity32 and diffuse @entity5055 without madarosis. The second @entity1 had extensive madarosis and abnormally curved, thin eyelashes with punctal and @entity3885 . Her marginal entropion was most prominent at the medial lower eyelids. The last @entity1 showed significant lash misdirection in a scattered distribution and patchy madarosis along with pseudomembranes blocking the puncta. All of these @entity3066 occurred soon after @entity1205 treatment for @entity0 . Such changes in the absence of questioning for previous @entity1205 use in history taking.

title: Cicatricial entropion following XXXX (Taxotere) therapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation', 'palpebral mucosal inflammation']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'advanced breast cancer']

entities_list: @entity9467 :: ('MESH:D007766', 'Disease') :: ['abnormalities and/or epiphora']

entities_list: @entity3885 :: ('MESH:D008173', 'Disease') :: ['canalicular obstruction']

entities_list: @entity3066 :: ('MESH:D005141', 'Disease') :: ['eyelid abnormalities']

entities_list: @entity5055 :: ('MESH:D058457', 'Disease') :: ['trichiasis']

entities_list: @entity32269 :: ('MESH:C535922', 'Disease') :: ['ophthalmic complaints']

entities_list: @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']

answer: @entity1205 :: (MESH:C067311,Chemical) :: ['docetaxel']


abstract: This study examined interactions between @entity859 ( @entity7308 ) and angiotensin II (ANG II) in controlling @entity8 ( @entity8 ) and glomerular filtration rate (GFR). In six normal @entity235 , intrarenal @entity7308 infusion (1.0 mumol/min) transiently decreased @entity8 , but during sustained @entity7308 infusion @entity8 increased to 122 +/- 7% of control, although GFR remained at 75 +/- 6% of control. Blockade of ANG II formation with the converting enzyme inhibitor SQ 14225 (n = 6) almost abolished the transient decrease in @entity8 but did not prevent the sustained fall in GFR caused by @entity7308 . When circulating ANG II was held constant by intravenous infusion of SQ 14225 and 20 ng . kg-1 . min-1 of ANG II (n = 6), @entity7308 transiently decreased @entity8 but the return of @entity8 was much slower than in normal @entity235 and @entity8 did not increase above control. Maintenance of constant circulating ANG II did not prevent @entity7308 -mediated decreases in GFR. These observations suggest that @entity7308 -mediated reductions in GFR do not depend entirely on ANG II and may be due to dilation of efferent arterioles by @entity7308 . However, the transient renal vasoconstriction caused by @entity7308 depends on ANG II, and data from this study suggest that part of the waning constrictor response to @entity7308 is due to suppression of @entity1122 secretion and endogenous ANG II formation. In circumstances where high ANG II levels are maintained (i.e., @entity177 ), @entity7308 may be capable of causing sustained renal vasoconstriction.

title: Interactions between XXXX and angiotensin II in controlling glomerular filtration.

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal blood flow', 'RBF']

entities_list: @entity859 :: ('MESH:D000241', 'Chemical') :: ['adenosine']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['ischemic renal failure']

answer: @entity859 :: (MESH:D000241,Chemical) :: ['adenosine']


abstract: OBJECTIVES: To assess the concomitant clinical improvement in incomplete @entity1566 @entity1 (SCIPs) suffering from @entity3501 ( @entity3501 ), neurogenic lower urinary tract symptoms (NLUTSs) and @entity323 ( @entity323 ) using sacral neuromodulation (SNM) for @entity3501 and NLUTSs. METHODS: Seventy-five SCIPs were selected. Before and during the follow-ups post-SNM, NLUTSs and @entity3501 were detected mainly through specific diaries. Erectile function was assessed using the International Index of Erectile Function composed of 5 questions (IIEF5). Quality of life (QoL) was measured with the Short Form 36 Health Survey questionnaire (SF-36). During the first stage, in which a permanent electrode was inserted percutaneously into the third sacral foramina and stimulated using an external generator, @entity1 with @entity3501 or NLUTSs were required to improve their symptoms by at least 50% compared with baseline before proceeding to the second stage in which the generator was placed in the @entity1 's buttock. @entity323 @entity1 needed to increase their IIEF5 score by at least 25% compared with baseline (evaluated initially 3 months after the second stage) in order to continue follow-up. RESULTS: Fourteen out of 37 subjects who manifested two functional pelvic dysfunctions at baseline maintained notable clinical improvement in two pelvic functions (median follow-up >3 years). Six had non-obstructive retention (NOR) and @entity323 , six double @entity322 , and two constipation with NOR. In the general and mental health domains of the SF-36, all @entity1 improved their scores by at least 20% compared with baseline. CONCLUSIONS: SNM may be beneficial to selected incomplete @entity29943 with concomitant pelvic functional disturbances.

title: Clinical concomitant benefits on pelvic floor dysfunctions after sacral neuromodulation in @entity1 with incomplete XXXX .

entities_list: @entity3501 :: ('MESH:D055496', 'Disease') :: ['NBSs', 'neurogenic bowel symptoms']

entities_list: @entity323 :: ('MESH:D007172', 'Disease') :: ['NED', 'neurogenic erectile dysfunction']

entities_list: @entity322 :: ('MESH:D014549', 'Disease') :: ['incontinence']

entities_list: @entity1566 :: ('MESH:D013119', 'Disease') :: ['spinal cord injury']

answer: @entity1566 :: (MESH:D013119,Disease) :: ['spinal cord injury']


abstract: OBJECTIVES: To assess the concomitant clinical improvement in incomplete @entity1566 @entity1 (SCIPs) suffering from @entity3501 ( @entity3501 ), neurogenic lower urinary tract symptoms (NLUTSs) and @entity323 ( @entity323 ) using sacral neuromodulation (SNM) for @entity3501 and NLUTSs. METHODS: Seventy-five SCIPs were selected. Before and during the follow-ups post-SNM, NLUTSs and @entity3501 were detected mainly through specific diaries. Erectile function was assessed using the International Index of Erectile Function composed of 5 questions (IIEF5). Quality of life (QoL) was measured with the Short Form 36 Health Survey questionnaire (SF-36). During the first stage, in which a permanent electrode was inserted percutaneously into the third sacral foramina and stimulated using an external generator, @entity1 with @entity3501 or NLUTSs were required to improve their symptoms by at least 50% compared with baseline before proceeding to the second stage in which the generator was placed in the @entity1 's buttock. @entity323 @entity1 needed to increase their IIEF5 score by at least 25% compared with baseline (evaluated initially 3 months after the second stage) in order to continue follow-up. RESULTS: Fourteen out of 37 subjects who manifested two functional pelvic dysfunctions at baseline maintained notable clinical improvement in two pelvic functions (median follow-up >3 years). Six had non-obstructive retention (NOR) and @entity323 , six double @entity322 , and two constipation with NOR. In the general and mental health domains of the SF-36, all @entity1 improved their scores by at least 20% compared with baseline. CONCLUSIONS: SNM may be beneficial to selected incomplete @entity29943 with concomitant pelvic functional disturbances.

title: Clinical concomitant benefits on pelvic floor dysfunctions after sacral neuromodulation in XXXX with incomplete @entity1566 .

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: A versatile strategy to endow dental implants with long-term antibacterial ability without compromising the cytocompatibility is highly desirable to combat implant-related @entity281 . @entity575 nanoparticles (Ag NPs) have been utilized as a highly effective and broad-spectrum antibacterial agent for surface modification of biomedical devices. However, the high mobility and subsequent hazardous effects of the particles on @entity1 cells may limit its practical applications. Thus, Ag NPs were immobilized on the surface of sand-blasted, large grit, and acid-etched (SLA) @entity702 by manipulating the @entity2653 heating effect of @entity575 plasma immersion ion implantation. The @entity575 plasma immersion ion implantation-treated SLA surface gave rise to both good antibacterial activity and excellent compatibility with @entity1 cells. The antibacterial activity rendered by the immobilized Ag NPs was assessed using @entity8209 and @entity794 , commonly suspected pathogens for peri-implant disease. The immobilized Ag NPs offered a good defense against multiple cycles of bacteria attack in both @entity8209 and @entity794 , and the mechanism was independent of @entity575 release. @entity8209 showed a higher susceptibility to Ag NPs than @entity794 , which might be explained by the presence of different wall structures. Moreover, the immobilized Ag NPs had no apparent toxic influence on the viability, proliferation, and differentiation of @entity35 bone marrow mesenchymal stem cells. These results demonstrated that good bactericidal activity could be obtained with very small quantities of immobilized Ag NPs, which were not detrimental to the @entity1 cells involved in the osseointegration process, and promising for @entity702 -based dental implants with commercial SLA surfaces.

title: Hierarchical micro/nanostructured XXXX with balanced actions to bacterial and @entity1 cells for dental implants.

entities_list: @entity1 :: ('9606', 'Species') :: ['mammalian']

entities_list: @entity8209 :: ('851', 'Species') :: ['F. nucleatum', 'Fusobacterium nucleatum']

entities_list: @entity2653 :: ('MESH:C538175', 'Disease') :: ['atomic-scale']

entities_list: @entity575 :: ('MESH:D012834', 'Chemical') :: ['Silver', 'silver']

entities_list: @entity794 :: ('1280', 'Species') :: ['Staphylococcus aureus', 'S. aureus']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity702 :: ('MESH:D014025', 'Chemical') :: ['titanium']

answer: @entity702 :: (MESH:D014025,Chemical) :: ['titanium']


abstract: A versatile strategy to endow dental implants with long-term antibacterial ability without compromising the cytocompatibility is highly desirable to combat implant-related @entity281 . @entity575 nanoparticles (Ag NPs) have been utilized as a highly effective and broad-spectrum antibacterial agent for surface modification of biomedical devices. However, the high mobility and subsequent hazardous effects of the particles on @entity1 cells may limit its practical applications. Thus, Ag NPs were immobilized on the surface of sand-blasted, large grit, and acid-etched (SLA) @entity702 by manipulating the @entity2653 heating effect of @entity575 plasma immersion ion implantation. The @entity575 plasma immersion ion implantation-treated SLA surface gave rise to both good antibacterial activity and excellent compatibility with @entity1 cells. The antibacterial activity rendered by the immobilized Ag NPs was assessed using @entity8209 and @entity794 , commonly suspected pathogens for peri-implant disease. The immobilized Ag NPs offered a good defense against multiple cycles of bacteria attack in both @entity8209 and @entity794 , and the mechanism was independent of @entity575 release. @entity8209 showed a higher susceptibility to Ag NPs than @entity794 , which might be explained by the presence of different wall structures. Moreover, the immobilized Ag NPs had no apparent toxic influence on the viability, proliferation, and differentiation of @entity35 bone marrow mesenchymal stem cells. These results demonstrated that good bactericidal activity could be obtained with very small quantities of immobilized Ag NPs, which were not detrimental to the @entity1 cells involved in the osseointegration process, and promising for @entity702 -based dental implants with commercial SLA surfaces.

title: Hierarchical micro/nanostructured @entity702 with balanced actions to bacterial and XXXX cells for dental implants.

answer: @entity1 :: (9606,Species) :: ['mammalian']


abstract: PURPOSE: The purpose of this study was to evaluate the prevalence of comorbidities and adverse events (AEs), and determine the treatment patterns according to @entity902 -sensitivity status in @entity1 with advanced (stage IIIB-IV) or recurrent @entity43 ( @entity43 ). METHODS: A cross-sectional study was carried out in France with @entity1 over 18 years, diagnosed with advanced (stage IIIB-IV) or recurrent @entity43 between 2009 and 2012. A total of 23 physicians (oncologists and gynecologists) participated, contributing 127 @entity1 . Data were abstracted by participating physicians into a case report form. RESULTS: Of the 127 @entity1 included, 92 (72.4%) had advanced @entity43 and 35 (27.6%) had recurrent @entity43 . A total of 73 comorbidities were reported in 44 @entity1 (34.6%). Vascular (10.2%), metabolic (7.1%), respiratory (5.5%), and @entity146 (5.5%) were the most common types of comorbidities reported. Prevalence of AEs was 74.8%, of which 12.6% were classified as serious. The most common AEs were @entity417 (16.5%), hematologic events (12.6%), taste change (11.8%), and @entity10 (7.1%). Throughout the follow-up period, twelve @entity1 @entity204 were reported (six due to disease progression). Of 35 @entity1 with recurrent disease, 16 were highly @entity902 sensitive (recurrence >12 months after stopping @entity902 -based therapy), eleven were partially @entity902 sensitive (recurrence 6-12 months after stopping @entity902 -based therapy), seven were @entity902 resistant (recurrence within 6 months of stopping @entity902 -based therapy or progression while receiving second- or later-line @entity902 -based therapy), and one was @entity902 refractory (recurrence within 6 months from the start of first-line @entity902 -based therapy). CONCLUSION: In this cross-sectional study of advanced and metastatic @entity43 @entity1 , approximately one-third of @entity1 were diagnosed with comorbidities, and approximately three-quarters were diagnosed with AEs (12.6% with severe AEs).

title: Cross-sectional study on comorbidities and adverse events in @entity1 with advanced and recurrent XXXX in France.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['EOC', 'ovarian cancer', 'epithelial ovarian cancer']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric disorders']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

entities_list: @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']

answer: @entity43 :: (MESH:D010051,Disease) :: ['ovarian cancer']


abstract: PURPOSE: The purpose of this study was to evaluate the prevalence of comorbidities and adverse events (AEs), and determine the treatment patterns according to @entity902 -sensitivity status in @entity1 with advanced (stage IIIB-IV) or recurrent @entity43 ( @entity43 ). METHODS: A cross-sectional study was carried out in France with @entity1 over 18 years, diagnosed with advanced (stage IIIB-IV) or recurrent @entity43 between 2009 and 2012. A total of 23 physicians (oncologists and gynecologists) participated, contributing 127 @entity1 . Data were abstracted by participating physicians into a case report form. RESULTS: Of the 127 @entity1 included, 92 (72.4%) had advanced @entity43 and 35 (27.6%) had recurrent @entity43 . A total of 73 comorbidities were reported in 44 @entity1 (34.6%). Vascular (10.2%), metabolic (7.1%), respiratory (5.5%), and @entity146 (5.5%) were the most common types of comorbidities reported. Prevalence of AEs was 74.8%, of which 12.6% were classified as serious. The most common AEs were @entity417 (16.5%), hematologic events (12.6%), taste change (11.8%), and @entity10 (7.1%). Throughout the follow-up period, twelve @entity1 @entity204 were reported (six due to disease progression). Of 35 @entity1 with recurrent disease, 16 were highly @entity902 sensitive (recurrence >12 months after stopping @entity902 -based therapy), eleven were partially @entity902 sensitive (recurrence 6-12 months after stopping @entity902 -based therapy), seven were @entity902 resistant (recurrence within 6 months of stopping @entity902 -based therapy or progression while receiving second- or later-line @entity902 -based therapy), and one was @entity902 refractory (recurrence within 6 months from the start of first-line @entity902 -based therapy). CONCLUSION: In this cross-sectional study of advanced and metastatic @entity43 @entity1 , approximately one-third of @entity1 were diagnosed with comorbidities, and approximately three-quarters were diagnosed with AEs (12.6% with severe AEs).

title: Cross-sectional study on comorbidities and adverse events in XXXX with advanced and recurrent @entity43 in France.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: PURPOSE: To evaluate how the growth of @entity2295 elsewhere (NVE) was delineated in an eye with @entity2994 (CRVO) using optical coherence tomography (OCT) angiography. @entity1 AND METHODS: We examined a 64-year-old @entity1 diagnosed with hemi-CRVO. The area around the occluded vein was scanned using a spectral-domain OCT device (RTVue XR Avanti). Blood flow was detected using the split-spectrum amplitude-decorrelation angiography (SSADA) algorithm. Color fundus photography, @entity941 angiography (FA), and OCT angiography examinations were performed at the first visit and at 3 and 6 months postpresentation. RESULTS: At the first visit, FA revealed delayed retinal @entity1211 and extensive areas of capillary nonperfusion. The @entity1 underwent a trial of intravitreal ranibizumab injection (0.5 mg/0.05 mL) for the treatment of @entity1103 . At 3 months postpresentation, there was no NVE around the occluded vein in the en-face SSADA image, but at 6 months, NVE appeared on the occluded veins. The en-face SSADA image showed the NVE structure in the fibrovascular membrane on the occluded vein more clearly than FA images. CONCLUSION: OCT angiography clearly visualized the sprouting of NVE in an eye with hemi-CRVO. New findings of the vascular structure of NVE in hemi-CRVO were revealed using the en-face SSADA algorithm.

title: En-face optical coherence tomography angiography of XXXX elsewhere in @entity2994 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'PATIENTS', 'man']

entities_list: @entity2994 :: ('MESH:D012170', 'Disease') :: ['hemicentral retinal vein occlusion']

entities_list: @entity2295 :: ('MESH:D015861', 'Disease') :: ['neovascularization']

entities_list: @entity1103 :: ('MESH:D008269', 'Disease') :: ['macular edema']

entities_list: @entity941 :: ('MESH:D019793', 'Chemical') :: ['fluorescein']

entities_list: @entity1211 :: ('MESH:D054556', 'Disease') :: ['venous filling']

answer: @entity2295 :: (MESH:D015861,Disease) :: ['neovascularization']


abstract: PURPOSE: To evaluate how the growth of @entity2295 elsewhere (NVE) was delineated in an eye with @entity2994 (CRVO) using optical coherence tomography (OCT) angiography. @entity1 AND METHODS: We examined a 64-year-old @entity1 diagnosed with hemi-CRVO. The area around the occluded vein was scanned using a spectral-domain OCT device (RTVue XR Avanti). Blood flow was detected using the split-spectrum amplitude-decorrelation angiography (SSADA) algorithm. Color fundus photography, @entity941 angiography (FA), and OCT angiography examinations were performed at the first visit and at 3 and 6 months postpresentation. RESULTS: At the first visit, FA revealed delayed retinal @entity1211 and extensive areas of capillary nonperfusion. The @entity1 underwent a trial of intravitreal ranibizumab injection (0.5 mg/0.05 mL) for the treatment of @entity1103 . At 3 months postpresentation, there was no NVE around the occluded vein in the en-face SSADA image, but at 6 months, NVE appeared on the occluded veins. The en-face SSADA image showed the NVE structure in the fibrovascular membrane on the occluded vein more clearly than FA images. CONCLUSION: OCT angiography clearly visualized the sprouting of NVE in an eye with hemi-CRVO. New findings of the vascular structure of NVE in hemi-CRVO were revealed using the en-face SSADA algorithm.

title: En-face optical coherence tomography angiography of @entity2295 elsewhere in XXXX .

answer: @entity2994 :: (MESH:D012170,Disease) :: ['hemicentral retinal vein occlusion']


abstract: PURPOSE: Urinary extravasation at the @entity254 is common after radical prostatectomies. Nevertheless, no data exist referring to the optimal date of catheter removal at the time of expected complete @entity3431 of the leakage. Thus, we developed over the last 10 years a standardized concept to check the @entity254 , evaluating urinary extravasation using a dynamic transrectal ultrasound ( @entity72306 ). METHODS: From 1999 to 2008, 1,479 radical prostatectomies have been performed. For complete @entity3431 , 752 could be evaluated using the standardized concept of checking the @entity254 . The first 250 @entity1 have been evaluated by cystogram and @entity72306 and the following 502 @entity1 only by @entity72306 postoperatively. The date of checking the @entity254 was determined by the urine color. RESULTS: Urinary extravasation could be detected 4-8 days postoperatively in 41% (n = 308), 9-12 days in 16% (n = 120), 13-20 days in 8% (n = 60), and in no @entity1 after 21 days. The coefficient of correlation comparing @entity72306 versus cystogram was r = 0.99, P < 0.05. The measured volume of urinary extravasation after 4-8 days postoperatively was 15 ml (3-49 ml) using @entity72306 and 16 ml (3-45 ml) using cystogram. After 9-20 days, the volume was determined as 9 ml (3-24 ml) by @entity72306 and 9 ml (4-23 ml) by cystogram. The macroscopic evaluation of the urinary color was very well correlated with the likelihood of extravasation being still present. When the urine was cloudy or colored by old blood, extravasation was present in 96.9% of the @entity1 . Microscopic evaluation like leukocyturia or @entity811 of the urine on the same day shows specificity in only 34.3%. CONCLUSIONS: Following radical prostatectomy, the urine color is essential to assess the chance of a persisting leakage at the @entity254 . The method of @entity72306 can replace the cystogram in checking for complete healing of the @entity254 , thus decreasing the exposure to @entity11898 of the @entity1 of about 60 cGy/cm(2).

title: New standardization of checking the vesicourethral XXXX for @entity3431 following radical prostatectomy with dynamic transrectal ultrasound: can this new technique replace the traditional postoperative cystogram?

entities_list: @entity3431 :: ('MESH:C536920', 'Disease') :: ['tightness']

entities_list: @entity254 :: ('MESH:C563598', 'Disease') :: ['anastomosis']

entities_list: @entity811 :: ('MESH:D006417', 'Disease') :: ['hematuria']

answer: @entity254 :: (MESH:C563598,Disease) :: ['anastomosis']


abstract: PURPOSE: Urinary extravasation at the @entity254 is common after radical prostatectomies. Nevertheless, no data exist referring to the optimal date of catheter removal at the time of expected complete @entity3431 of the leakage. Thus, we developed over the last 10 years a standardized concept to check the @entity254 , evaluating urinary extravasation using a dynamic transrectal ultrasound ( @entity72306 ). METHODS: From 1999 to 2008, 1,479 radical prostatectomies have been performed. For complete @entity3431 , 752 could be evaluated using the standardized concept of checking the @entity254 . The first 250 @entity1 have been evaluated by cystogram and @entity72306 and the following 502 @entity1 only by @entity72306 postoperatively. The date of checking the @entity254 was determined by the urine color. RESULTS: Urinary extravasation could be detected 4-8 days postoperatively in 41% (n = 308), 9-12 days in 16% (n = 120), 13-20 days in 8% (n = 60), and in no @entity1 after 21 days. The coefficient of correlation comparing @entity72306 versus cystogram was r = 0.99, P < 0.05. The measured volume of urinary extravasation after 4-8 days postoperatively was 15 ml (3-49 ml) using @entity72306 and 16 ml (3-45 ml) using cystogram. After 9-20 days, the volume was determined as 9 ml (3-24 ml) by @entity72306 and 9 ml (4-23 ml) by cystogram. The macroscopic evaluation of the urinary color was very well correlated with the likelihood of extravasation being still present. When the urine was cloudy or colored by old blood, extravasation was present in 96.9% of the @entity1 . Microscopic evaluation like leukocyturia or @entity811 of the urine on the same day shows specificity in only 34.3%. CONCLUSIONS: Following radical prostatectomy, the urine color is essential to assess the chance of a persisting leakage at the @entity254 . The method of @entity72306 can replace the cystogram in checking for complete healing of the @entity254 , thus decreasing the exposure to @entity11898 of the @entity1 of about 60 cGy/cm(2).

title: New standardization of checking the vesicourethral @entity254 for XXXX following radical prostatectomy with dynamic transrectal ultrasound: can this new technique replace the traditional postoperative cystogram?

answer: @entity3431 :: (MESH:C536920,Disease) :: ['tightness']


abstract: The immunoperoxidase technique, using antibodies against @entity1 urinary urokinase (Mr 55,000), was used for the localization of this enzyme in histological preparations of @entity1 @entity694 and normal colon tissue. The localization of tissue (vascular) activator was also investigated using antibodies against enzyme purified from @entity1 @entity320 . Both the "indirect method" and the peroxidase-antiperoxidase technique were found to be useful. Urokinase-reactive material was found in all tissues examined (33 primary @entity5 , 11 @entity3 , and 8 @entity652 ). In the normal colon, urokinase was found only in some of the goblet cells of the mucosal epithelium. In @entity694 , diffuse specific staining was observed in the cytoplasm, but the most intense staining was localized at the edge of the @entity5 cells bordering the lumen of the glands. In some cases, intense supranuclear staining could be observed in a location corresponding to the Golgi apparatus. In a few instances, urokinase could be seen associated with fibroblasts near the advancing front of an invading @entity5 . @entity652 , a @entity5 but often a precursor of @entity5 , also showed the presence of urokinase. Most significant were the observations showing that, in regions of the mucosal glands where normal epithelial cells were abruptly replaced by @entity5 cells, the appearance of cytoplasmic urokinase showed strict and exclusive association with the malignant cells, and the same was the case in transitions from normal epithelium to @entity652 . In contrast to urokinase, @entity1456 was not associated with @entity5 cells, but was consistently present in the stroma which separates the @entity5 glands and was localized in the endothelium of the blood vessels. This visual evidence was supported by results of extraction of plasminogen activators from @entity5 , and from the separated mucosal and submucosal layers of the normal colon of the same @entity1 , which showed that urokinase is most abundant in the @entity5 tissue and least abundant in the submucosa, while tissue activator is most prevalent in the well-vascularized mucosa and submucosa and scarce in the usually poorly vascularized @entity420 .

title: Localization of plasminogen activators in @entity1 XXXX by immunoperoxidase staining.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'benign tumor', 'cancers', 'cancer', 'tumors']

entities_list: @entity1456 :: ('100128998', 'Gene') :: ['tissue plasminogen activator']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity652 :: ('MESH:D000236', 'Disease') :: ['Adenoma', 'adenomas', 'adenoma']

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colon tumors', 'colon cancer']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['malignant melanoma']

answer: @entity694 :: (MESH:D003110,Disease) :: ['colon cancer']


abstract: The immunoperoxidase technique, using antibodies against @entity1 urinary urokinase (Mr 55,000), was used for the localization of this enzyme in histological preparations of @entity1 @entity694 and normal colon tissue. The localization of tissue (vascular) activator was also investigated using antibodies against enzyme purified from @entity1 @entity320 . Both the "indirect method" and the peroxidase-antiperoxidase technique were found to be useful. Urokinase-reactive material was found in all tissues examined (33 primary @entity5 , 11 @entity3 , and 8 @entity652 ). In the normal colon, urokinase was found only in some of the goblet cells of the mucosal epithelium. In @entity694 , diffuse specific staining was observed in the cytoplasm, but the most intense staining was localized at the edge of the @entity5 cells bordering the lumen of the glands. In some cases, intense supranuclear staining could be observed in a location corresponding to the Golgi apparatus. In a few instances, urokinase could be seen associated with fibroblasts near the advancing front of an invading @entity5 . @entity652 , a @entity5 but often a precursor of @entity5 , also showed the presence of urokinase. Most significant were the observations showing that, in regions of the mucosal glands where normal epithelial cells were abruptly replaced by @entity5 cells, the appearance of cytoplasmic urokinase showed strict and exclusive association with the malignant cells, and the same was the case in transitions from normal epithelium to @entity652 . In contrast to urokinase, @entity1456 was not associated with @entity5 cells, but was consistently present in the stroma which separates the @entity5 glands and was localized in the endothelium of the blood vessels. This visual evidence was supported by results of extraction of plasminogen activators from @entity5 , and from the separated mucosal and submucosal layers of the normal colon of the same @entity1 , which showed that urokinase is most abundant in the @entity5 tissue and least abundant in the submucosa, while tissue activator is most prevalent in the well-vascularized mucosa and submucosa and scarce in the usually poorly vascularized @entity420 .

title: Localization of plasminogen activators in XXXX @entity694 by immunoperoxidase staining.

answer: @entity1 :: (9606,Species) :: ['human']


abstract: The ascending projections of the mammillary region of the hypothalamus and adjacent posterolateral hypothalamus were investigated by autoradiographic and horseradish peroxidase histochemical techniques. Analysis of the anterograde data revealed that the main contingent of mammillary fibers ascends in the medial forebrain bundle (MFB) in the lateral hypothalamic area. These fibers distribute to a number of @entity4519 regions via three pathways. (1) Fibers course dorsomedially into the medial and lateral parts of the septum and continue into the hippocampus with a dense terminal field in the parahippocampal area. (2) Laterally coursing fibers project to area corticoidea dorsolateralis, area temporo-parieto-occipitalis, cortex piriformis, and the posterior part of archistriatum. (3) The fibers remaining in the MFB ascend into the "ventral paleostriatum," olfactory tubercle, and into the lateral and ventral borders of the rostral portion of lobus parolfactorius (LPO). Numerous fibers leave the LPO region and course dorsally into the deep layer of the Wulst, @entity27202 ( @entity27202 ). Many fibers continue dorsolaterally through the @entity27202 and enter an unnamed region of the dorsolateral telencephalon (lateral to the vallecula) at the level of the olfactory bulb. Retrograde transport experiments revealed that the perikarya of origin-of-fiber projections to the parahippocampal area and to the rostral, dorsolateral telencephalon reside not only in nucleus mammillaris lateralis but also in posterolateral hypothalamic cells rostral and dorsal to this nucleus. The projection of these hypothalamic cells to the hippocampal formation and many other @entity4519 regions in birds suggests that these cells are similar to the @entity1 supramammillary nucleus and posterolateral hypothalamus rather than the mammillary nuclei.

title: Ascending projections of the mammillary region in the pigeon: emphasis on XXXX connections.

entities_list: @entity1 :: ('9606', 'Species') :: ['mammalian']

entities_list: @entity4519 :: ('MESH:C536954', 'Disease') :: ['telencephalic']

entities_list: @entity27202 :: ('MESH:C538109', 'Disease') :: ['hyperstriatum dorsale', 'HD']

answer: @entity4519 :: (MESH:C536954,Disease) :: ['telencephalic']


abstract: BACKGROUND: This study retrospectively describes the outcome of a series of 38 @entity1 (pts) with T4 @entity189 exclusively treated by radio and chemotherapy. @entity1 AND METHODS: From 1992 to 2007, 38 pts with UST4-N0-2-M0 @entity189 were treated with exclusive radiotherapy and chemotherapy. All @entity1 received external beam radiotherapy (EBRT) (median dose 45   Gy) with a concomitant chemotherapy (5- @entity1487 - @entity900 ). Eleven @entity1 received neo-adjuvant chemotherapy (5- @entity1487 - @entity900 ). After 2-8 weeks, a 15-20   Gy boost was delivered either with EBRT (20 pts) or interstitial (192)Ir brachytherapy (18 pts). Mean follow-up was 66 months. RESULTS: After chemoradiation therapy (CRT), 13 pts (34%) had a complete response, 23 pts (60%) a response >50% (2 pts were not evaluated). The 5-year-disease-free survival was 79.2        6.5%, and the 5-year overall survival was 83.9        6%. Eight @entity1 developed @entity5 progression (mean delay 8.8 months), six of them requiring a salvage surgery with definitive colostomy for local relapse. Late severe complication requiring colostomy was observed in 2 pts. The 5-year-colostomy-free survival was 78        6.9%. @entity1 who received primary chemotherapy had a statistically significant better 5-year colostomy-free survival (100% vs. 38        16.4%, P   =   0.0006). CONCLUSION: T4 @entity189 can be treated with a curative intent using a sphincter-sparing approach of CRT, and neo-adjuvant chemotherapy should be considered prior to radiotherapy.

title: Is neoadjuvant chemotherapy prior to radio-chemotherapy beneficial in T4 XXXX ?

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['anal carcinoma']

entities_list: @entity1487 :: ('MESH:D005472', 'Chemical') :: ['fluorouracil']

answer: @entity189 :: (MESH:D002277,Disease) :: ['anal carcinoma']


abstract: @entity1162 , LQTS, results in serious @entity65 , such as @entity591 and @entity1164 . A promiscuous binding of different drugs to the intracavitary binding site in the pore domain (PD) of @entity1 ether-a-go-go related gene ( @entity9493 ) channels leads to a similar dysfunction, known as a drug-induced LQTS. Therefore, an assessment of the blocking ability for potent drugs is of great pragmatic value for molecular pharmacology and medicinal chemistry of hERGs. Thus, we attempted to create an in silico model aimed at blinded drug screening for their blocking ability to the @entity9678 PD. Two distinct approaches to the drug blockage, ligand-based QSAR and receptor-based molecular docking methods, are combined for development of a universal pharmacophore model, which provides rapid assessment of drug blocking ability to the @entity9678 channel. The best 3D-QSAR model (AAADR.7) from PHASE modeling was selected from a pool consisting of 44 initial candidates. The constructed model using 31 @entity9493 blockers was validated with 9 test set compounds. The resulting model correctly predicted the pIC(50) values of test set compounds as true unknowns. To further evaluate the pharmacophore model, 14 @entity9493 blockers with diverse @entity9493 blocking potencies were selected from literature and they were used as additional external blind test sets. The resulting average deviation between in vitro and predicted pIC(50) values of external test set blockers is found as 0.29 suggesting that the model is able to accuretely predict the pIC(50) values as true unknowns. These pharmacophore models were merged with a previously developed atomistic receptor model for the @entity9678 PD and exhibited a high consistency between ligand-based and receptor-based models. Therefore, the developed 3D-QSAR model provides a predictive tool for profiling candidate compounds before their synthesis. This model also indicated the key functional groups determining a high-affinity blockade of the @entity9678 channel. To cross-validate consistency between the constructed @entity9678 pore domain and the pharmacophore models, we performed docking studies using the homology model of @entity9678 . To understand how polar or nonpolar moieties of inhibitors stimulate channel inhibition, critical @entity535 replacement (i.e., T623, S624, S649, Y652 and F656) at the @entity9493 cavity was examined by in silico mutagenesis. The average docking score differences between wild type and mutated @entity9493 channels was found to have the following order: @entity34691 > @entity34690 > @entity72307 > @entity66811 > @entity72308 . These results are in agreement with experimental data.

title: Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the XXXX pore domain.

entities_list: @entity1164 :: ('MESH:D016757', 'Disease') :: ['sudden cardiac death']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

entities_list: @entity591 :: ('MESH:D013610', 'Disease') :: ['tachyarrhythmia']

entities_list: @entity1162 :: ('MESH:D008133', 'Disease') :: ['Long QT syndrome']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disorders']

answer: @entity9678 :: (3757,Gene) :: ['hERG1']


abstract: The purpose of the follow-up study was to determine whether modern therapy with @entity17979 and/or valproate with/without @entity109 and its derivatives improves the longterm prognosis of @entity2048 as compared to formerly used treatments. The @entity1 population consisted of 194 cases (88 @entity1 , 106 @entity1 ) with spike wave @entity302 starting with absences. In each case the diagnosis was confirmed by clinical observation and the typical EEG pattern. Only those @entity1 were included who could be followed beyond the eighteenth year of life (up to age 45). The sample includes also older @entity1 diagnosed during the fifties, before the present standard therapy was available. Because of the heterogeneity of the material and its selection, the data obtained are not suited to make a general statement about the ultimate prognosis of absences. The results demonstrate the effectiveness of regularly applied modern treatment. 72 out of 194 @entity1 (37%) manifested generalized @entity410 (gtcs) during the course: 20 of these @entity1 showed only incidental generalized @entity410 , which were not dependent on therapy. In 52 cases gtcs appeared without relation to precipitating factors. None of these @entity1 received regular standard therapy before onset of gtcs. In 31 cases absence statuses were observed. These @entity1 did not have an unfavourable outcome provided the standard therapy was instituted early and consequently. A change from @entity2048 into an @entity302 with complex partial @entity410 sensu strictiori could not be observed. At final investigation 42 of 194 @entity1 still had @entity410 : 7 with absences, 35 with grand mal with or without absences.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Longterm follow-up of childhood @entity302 with absences. I. XXXX with absences at onset.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'girls', 'boys']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['tonic clonic seizures', 'seizures']

entities_list: @entity109 :: ('MESH:D010634', 'Chemical') :: ['phenobarbitone']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

entities_list: @entity2048 :: ('MESH:D004832', 'Disease') :: ['absence epilepsy']

entities_list: @entity17979 :: ('MESH:D005013', 'Chemical') :: ['ethosuximide']

answer: @entity302 :: (MESH:D004827,Disease) :: ['Epilepsy']


abstract: The purpose of the follow-up study was to determine whether modern therapy with @entity17979 and/or valproate with/without @entity109 and its derivatives improves the longterm prognosis of @entity2048 as compared to formerly used treatments. The @entity1 population consisted of 194 cases (88 @entity1 , 106 @entity1 ) with spike wave @entity302 starting with absences. In each case the diagnosis was confirmed by clinical observation and the typical EEG pattern. Only those @entity1 were included who could be followed beyond the eighteenth year of life (up to age 45). The sample includes also older @entity1 diagnosed during the fifties, before the present standard therapy was available. Because of the heterogeneity of the material and its selection, the data obtained are not suited to make a general statement about the ultimate prognosis of absences. The results demonstrate the effectiveness of regularly applied modern treatment. 72 out of 194 @entity1 (37%) manifested generalized @entity410 (gtcs) during the course: 20 of these @entity1 showed only incidental generalized @entity410 , which were not dependent on therapy. In 52 cases gtcs appeared without relation to precipitating factors. None of these @entity1 received regular standard therapy before onset of gtcs. In 31 cases absence statuses were observed. These @entity1 did not have an unfavourable outcome provided the standard therapy was instituted early and consequently. A change from @entity2048 into an @entity302 with complex partial @entity410 sensu strictiori could not be observed. At final investigation 42 of 194 @entity1 still had @entity410 : 7 with absences, 35 with grand mal with or without absences.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Longterm follow-up of childhood XXXX with absences. I. @entity302 with absences at onset.

answer: @entity302 :: (MESH:D004827,Disease) :: ['epilepsy']


abstract: BACKGROUND: @entity472 shares some ethiopathological features with @entity731 and increasing evidence links Toll-like receptors (TLRs) to atherogenesis. METHODS: TLR-mediated @entity32 and osteogenesis were investigated in @entity1 interstitial cells isolated from stenotic and non-stenotic aortic valves. TLR expression and signalling were evaluated by quantitative RT-PCR, flow cytometry, Western blot analysis, ELISA, and cytokine arrays. Osteogenesis was evaluated by measuring alkaline phosphatase activity. RESULTS: Interstitial cells from control valves express most TLRs, being @entity2939 the most abundant, whereas cells from stenotic valves express higher @entity2939 and @entity2938 and lower @entity20040 and @entity6801 transcript levels. When pro-inflammatory pathways were analyzed, we observed that @entity2939 , @entity2938 and @entity6800 ligands induced an early activation of NF-kB and @entity1435 MAPK activation in cells from control and stenotic valves. Strikingly, when TLRs sensing viral patterns were studied, a sustained @entity6800 -mediated activation of NF-kB, a kB-independent induction of catalytically active @entity2247 and @entity2071 expression, and induction of expression of several chemokines were observed. @entity2939 , but not @entity2938 , engagement produced a similar but NF-kB-dependent effect. Moreover, @entity6800 and @entity2939 agonists induced alkaline phosphatase expression and activity. CONCLUSIONS: Exposure of aortic valve interstitial cells to viral and Gram-negative bacteria molecular patterns induces distinct and long-term TLR-mediated pro-inflammatory and pro-osteogenic responses that might be relevant to the pathogenesis of @entity472 .

title: Viral and bacterial patterns induce TLR-mediated sustained XXXX and calcification in aortic valve interstitial cells.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis']

entities_list: @entity472 :: ('MESH:D001024', 'Disease') :: ['Aortic stenosis', 'degenerative aortic stenosis']

answer: @entity32 :: (MESH:D007249,Disease) :: ['inflammation']